Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?

We recently published a list of Was Jim Cramer Right About These 11 Stocks? In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other stocks that Jim Cramer discusses.

A caller asked about Sarepta Therapeutics Inc. (NASDAQ:SRPT), a biotech firm working on RNA therapies. Cramer responded with cautious optimism:

“You know what, I have not looked at it lately — what it’s doing with RNA and some really tough diseases. It has been a company that has not made money, but is about to break out and make money. I’m not going to say no to it.”

Despite being cautiously positive, Cramer missed this one as Sarepta plunged 68.98%. Sarepta Therapeutics Inc. (NASDAQ: SRPT) is focused on precision genetic medicine, including RNA therapies for rare neuromuscular diseases like Duchenne muscular dystrophy.

A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals.

As of 2025, Cramer has changed his opinion on the stock. Here’s what he said on the 15^th of January when asked about it:

“You’re totally right. I think the RNA-based therapeutic companies are not doing well. I wonder if this isn’t like a reverse halo effect because of Moderna. I didn’t quite understand, I agree with you. It, it is troubling. I don’t want to be there.”

Overall, SRPT ranks 2nd on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of SRPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SRPT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.